Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study.

Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study. J Clin Oncol. 2011 Sep 01; 29(25):3389-95.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Combined Chemotherapy Protocols
Bendamustine Hydrochloride
Boronic Acids
Bortezomib
Dose-Response Relationship, Drug
Drug Resistance, Neoplasm
Female
Follow-Up Studies
Humans
Lymphoma, Follicular
Male
Maximum Tolerated Dose
Middle Aged
Neoplasm Recurrence, Local
Nitrogen Mustard Compounds
Pyrazines
Rituximab
Salvage Therapy
Survival Rate
Treatment Outcome

authors with profiles

NATHAN FOWLER